Laekna Therapeutics Receives IND Approvals in China and US for Phase Ib/III Global Multi-center Clinical Study of Afuresertib in combination with fulvestrant for patients with HR+/HER2- breast cancer ...Middle East

SHANGHAI and WAREN, New Jersey, Aug. 26, 2021 /PRNewswire/ -- Laekna Therapeutics announced today that the Center for Drug Evaluation (CDE), the National Medical Products Administration (NMPA) of China has approved the Investigational New Drug (IND) application of its Category 1 new drug...

Read More Details
Finally We wish PressBee provided you with enough information of ( Laekna Therapeutics Receives IND Approvals in China and US for Phase Ib/III Global Multi-center Clinical Study of Afuresertib in combination with fulvestrant for patients with HR+/HER2- breast cancer )

Also on site :

• Syria Launches New National Visual Identity
• Supreme Court clears way for deportation to South Sudan of several immigrants with no ties there
• Legendary Seafood Company Files for Chapter 11 Bankruptcy